The UroOnc Minute: Neoadjuvant Therapy Before Radical Prostatectomy, With Isaac Y. Kim, MD, PhD, MBA
Isaac Y. Kim, MD, PhD, MBA, joins to discuss the evolving data surrounding neoadjuvant therapy before radical prostatectomy in prostate cancer.
|Podcasts|June 28, 2022
Dr. Laviana on decisional regret after prostate cancer treatment
Author(s)Urology Times staff
“Localized prostate cancer is a very complicated disease space,” says Aaron A. Laviana, MD, MBA.
Advertisement
In this episode, Urology Times® spoke with Dr. Aaron Laviana, who discusses decisional regret in patients with prostate cancer. Laviana is an assistant professor of surgery and perioperative care and a courtesy faculty member of the department of oncology at The University of Texas at Austin Dell Medical School.
Advertisement
Related to this article
Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.
Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Heather Florio joins to discuss the potential role of supplements in pelvic and sexual health.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
The phase 3 BiPASS trial is evaluating the use of 68Ga-PSMA-PET in combination with MRI for pre-biopsy prostate cancer detection.
In RTOG 3506, adding enzalutamide to standard ADT and salvage radiotherapy was associated with 2-year PFS benefit.
In the phase 3 PACE-A trial, SBRT and prostatectomy showed similar 8-year disease control in localized prostate cancer, with lower rates of urinary incontinence after SBRT.
Advertisement
Advertisement
Trending on Urology Times
1
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
2
AMA issues Category I CPT codes for implantable tibial neuromodulation in UUI
3
FDA updates in urology: September 2026
4
Enzalutamide plus salvage radiotherapy associated with improved PFS in high-risk BCR
5